CA Intermediate · Advanced Accounting · AS 26 Intangible Assets
Anand Ltd. acquired a patent on 1 April 2023 for Rs 20,00,000 with useful life of 10 years, amortised straight-line, nil residual. On 31 March 2026 the recoverable amount of the patent is Rs 11,00,000. Ignoring other factors, what is the net carrying amount at 31 March 2026 after considering impairment under AS 28, and the amortisation charged for 2026-27 if the remaining life stays at 7 years?
The carrying amount becomes Rs 11,00,000 and the next year's amortisation is Rs 1,57,143. After three years of amortisation the book value is Rs 14,00,000, which exceeds the recoverable amount, so Rs 3,00,000 is written off, and Rs 11,00,000 is spread over the remaining seven years.
- ARs 11,00,000 and Rs 1,57,143Correct
- BRs 14,00,000 and Rs 2,00,000
- CRs 11,00,000 and Rs 2,00,000
- DRs 14,00,000 and Rs 1,57,143
Explanation
Accumulated amortisation for 3 years = 2,00,000 x 3 = 6,00,000; carrying amount = 14,00,000. Recoverable amount 11,00,000 is lower, so impairment loss is 3,00,000 and the carrying amount becomes 11,00,000. Revised amortisation = 11,00,000/7 = 1,57,143. Options keeping 14,00,000 ignore impairment.
Did you get it right without looking?
One question tells you little. A timed set on AS 26 Intangible Assets shows your real accuracy, how long you take and where you lose marks.
More AS 26 Intangible Assets questions
- Sharma Foods Ltd. incurred the following during the year: advertising campaign Rs 6,00,000; staff training costs Rs 2,50,000; start-up costs…
- Veda Pharma Ltd. incurred Rs 18 lakh on a research phase and Rs 30 lakh on a development phase for a new drug formulation during 2025-26. Th…
- Ravi Ltd. acquired a franchise right by paying Rs 5,00,000 in cash and issuing 10,000 equity shares of face value Rs 10 each, whose fair val…
- Veda Pharma Ltd. spent ₹40 lakh during 2025-26 on a research phase to find a new drug formulation. In the same year it spent ₹25 lakh on an …
- Mehta Foods Ltd. spent Rs 9,00,000 on a national advertising campaign for a new brand and Rs 4,00,000 on staff training for the launch durin…
- Kaveri Pharma Ltd. acquired a patent on 1 April 2023 for Rs 40,00,000 with a legal life of 10 years. Management expects it to generate benef…